3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Oxaliplatin
112
Fluorouracil
104
Leucovorin
91
Irinotecan
91
Capecitabine
59
Bevacizumab
58
Cetuximab
46
Folfox protocol
28
Colonoscopy
24
Panitumumab
19
Chemotherapy, Adjuvant
19
Blood Specimen Collection
19
Drug Therapy
18
Nivolumab
17
Magnetic Resonance Spectroscopy
17
Radiotherapy
16
Exercise
16
Early Intervention, Educational
16
Surveys and Questionnaires
15
Laparoscopy
15
Surgical Procedures, Operative
13
Floxuridine
13
Biopsy
13
trifluridine tipiracil drug combination
12
pembrolizumab
12
XELOX
12
Neoadjuvant Therapy
11
Methods
11
Immunohistochemistry
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Colonic Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts